Pharma and Big Tech Deepen AI Drug Discovery Partnerships as Pipeline Accelerates

Pharmaceutical and technology companies are expanding collaborations that harness artificial intelligence to accelerate drug discovery, marking a fundamental shift in how medicines are developed. In recent weeks, Denmark's Zealand Pharma committed up to $1.2 billion to Generate Biomedicines for AI-powered obesity treatments, while Eli Lilly launched a co-innovation lab with NVIDIA to apply advanced computing to pharmaceutical research. Isomorphic Labs, Alphabet's AI drug-discovery subsidiary, is in funding talks valuing the company at least $40 billion—reflecting investor confidence in AI-discovered therapeutics even as the field awaits its first FDA approval.